Skip to main content
Clinical Trials/JPRN-UMIN000004332
JPRN-UMIN000004332
Completed
Phase 1

Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer. - Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer.

Tokyo Women's Medical University0 sites20 target enrollmentOctober 6, 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Pancreatic cancer
Sponsor
Tokyo Women's Medical University
Enrollment
20
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 6, 2010
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Tokyo Women's Medical University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\.Pregnancy or lactation 2\.Decision of unsuitableness by principal investigatior 3\.Patient with severe underlying disease 4\.Patient with severe allergy disease

Outcomes

Primary Outcomes

Not specified

Similar Trials